Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Granisetron°ú Dexamethasone º´Çà ¿ä¹ýÀÇ Áö¿¬¼º ¿À½É ¹× ±¸Åä¿¡ ´ëÇÑ È¿°ú Effect of Granisetron Plus Dexamethasone in the Prevention of Delayed Nausea and Vomiting

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 4È£ p.690 ~ 699
¼Ò¼Ó »ó¼¼Á¤º¸
½ÉÁ¤¿ì/Jeong Woo Shim ÀÌ¿ë¼·/±èÈï¾÷/Á¤°æ¿ø/¹Ú¿µÈ£/À弼ȣ/ȲÁø¿ë/ÀåÁ¤¼ø/ÀÌÁ¾¼®/Yong Seop Lee/Heung Up Kim/Geong Won Jung/Yeong Ho Park/Se Ho Chang/Jin Yong Whang/Jeong Soon Jang/Jong Seok Lee

Abstract

°á·Ð
º» ¿¬±¸ °á°ú °íÇü¾ÏÀ¸·Î °í¿ë·®ÀÇ cisplatinÀ» Æ÷ÇÔÇÑ º¹ÇÕ È­Çпä¹ýÀ» ¹ÞÀº 64¸íÀÇ È¯ÀÚ
¸¦ ´ë»óÀ¸·Î ½ÃÇàÇÑ granisetron°ú dexamethasoneÀÇ Áö¿¬¼º ¿À½É ¹× ±¸Åä¿¡ ´ëÇÑ ¿¹¹æ È¿
°ú´Â ´ÙÀ½°ú °°´Ù. Áö¿¬¼º ¿À½É¿¡ À־ 37¿¹(58%)¿¡¼­, Áö¿¬¼º ±¸Åä¿¡ À־´Â 54¿¹
(84%)¿¡¼­ È¿°ú°¡ ÀÖ¾ú´Ù. ¶ÇÇÑ ECOG performance scaleÀÌ ÁÁÀº °æ¿ì¿Í ±Þ¼º ¿À½É ¹× ±¸
Åä°¡ Àß Á¶ÀýµÈ °æ¿ì Áö¿¬¼º ¿À½É ¹× ±¸ÅäÀÇ Á¶Àý È¿°ú°¡ ´õ ÁÁ¾Ò´Ù. Granisetron°ú
dexamethasoneÀÇ º´¿ë ¿ä¹ýÀº 1ȸÀÇ °í¿ë·®ÀÇ cisplatinÀ» Åõ¿© ¹Þ´Â ȯÀڵ鿡°Ô Ưº°ÇÑ ºÎ
ÀÛ¿ë ¾øÀÌ ±Þ¼º ¿À½É»Ó ¾Æ´Ï¶ó Áö¿¬¼º ¿À½É ¹× ±¸Åä¿¡µµ ¸¹Àº µµ¿òÀÌ µÉ °ÍÀ¸·Î »ç·áµÈ´Ù.
#ÃÊ·Ï#
Background: Granisetron, a new 5-HT3 receptor antagonist, was reported
as a highly effective antiemetics, especially in combination with dexamethasone, in the
prevention of acute emesis induced by cisplatin. But there is lack of data about
effectiveness in the prevention of delayed emesis. In this study, the efficacy of
granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin
was evaluated.
Materials and Methods: Sixty-four patients who were to receive high-dose cisplatin
containing chemotherapy regimen were enrolled in this study. They were received 20 mg
of dexamethasone and 3 mg of granisetron at 30 min and 10 minutes prior to cisplatin
infusion, respectively. They were monitored for 5 days, first 24 hours for acute
nausea/vomiting and the subsequent 4 days for delayed nausea/vomiting. Antiemetic
effect of granisetron was evaluated according to the criteria of Italian Group of
Antiemetic Research.
Results: Control of delayed nausea and vomiting was achieved in 58% and 84%,
respectively. Eastern Cooperative Oncology Group performance status was a statistically
significant prognostic factor for control of acute vomiting and delayed nausea/vomiting.
There were no stastically significant differences between control of delayed
nausea/vomiting and other prognostic factors, including sex, age, and prior history of
cisplatin therapy. The antiemetic effect was greater in the patients who had controled
acute nausea/vomiting than those who had not.
Conclusion: Granisetron plus dexamethasone is an excellent regimen in the control of
not only acute emesis but also delayed emesis induced by high-dose cisplatin
chemotherapy.

Å°¿öµå

Granisetron; Dexamethasone; Cisplatin; Emesis; Serotonin;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS